Epigenetics in Immune-Mediated Disease

 pigenetics can be defined as the collective modifications in the chemical structure of DNA and histone proteins, without altering the basic DNA nucleotide sequence. This can result in changes in gene expression primarily via regulating chromatin accessibility. Gene expression can also be altered by non-coding RNAs which have been increasingly recognized to be expressed throughout the genome. Understanding epigenetic modifications and the functional implications of individual epigenetic marks has helped to illuminate the complexity of mammalian genomes and has provided important insights into the regulatory role of intergenic and non-protein-coding genomic regions. 


In addition, genetic-epigenetic interaction, whereby disease-associated genetic variants directly or indirectly influence locus-specific epigenetic modifications, can provide mechanistic implications for disease-associated genetic variants in immune-mediated diseases.

Comments

Post a Comment

Popular posts from this blog

Immunodermatology studies skin

Image
Immunodermatology studies skin as an organ of impunity in health and conditions. Several areas like print-immunology (goods of UV light on skin defense), seditious conditions like Hidradenitis Suppurativa, antipathetic contact dermatitis and atopic eczema, presumably autoimmune conditions like vitiligo and psoriasis, and eventually the immunology of microbial skin conditions similar as retrovirus infection and leprosy.  Cutaneous Dendritic Cells in Health and Disease Photo immunology Atopic Dermatitis Non-melanoma Skin Cancer Immunobiology & Immune-Based Therapies Drug Eruptions Immunodermatology & Viral Skin Infection Clinical Dermatology Cutaneous T-Cell Lymphoma Allergic Urticaria Alopecia Areata Cutaneous Lupus Erythematosus Pemphigoid Spectrum Epidermolysis Bullosa Acquisita Immunoglobulin Dermatitis Advances in Immuno-Dermatology
Read more

Tumor-agnostic treatment treatments approved

Image
  Tumor-agnostic treatment is a drug treatment that is used to treat any kind of cancer, regardless of where in the body it started or the type of tissue from which it developed. This type of treatment can be used when the tumor has a very specific molecular alteration that is targeted by the drug or predicts that the drug is likely to work. Pembrolizumab was the first drug to be approved with a tumor-agnostic indication. Pembrolizumab is a type of immunotherapy, a drug that works by releasing the brakes on the immune system. In 2017, pembrolizumab was approved by the FDA to treat adults and children with solid tumors that have spread, called metastatic, or that cannot be treated with surgery, called unresectable. These tumors must also have a molecular alteration called microsatellite instability-high (MSI-H) or DNA mismatch repair deficiency (dMMR). Tumors that have MSI-H or dMMR have difficulty repairing damage to their DNA. As a result, they often develop large numbers of mut...
Read more

ER- Phagy Is Involved in the declination of Collagen I by IL- 1β in mortal Amnion in labor

Image
The process of labor is associated with inflammation within the uterine apkins, and IL- 1β is a crucial proinflammatory cytokine involved. Autophagy is arising as an important pathway to remove spare cellular factors. still, it isn't known whether IL- 1β employs the autophagy pathway to degrade collagen, thereby sharing in membrane rupture at labor. In this study, we delved this issue in mortal amnion. Results showed that IL- 1β situations were significantly increased in mortal amnion attained from deliveries with robotic labor and membrane rupture, which was accompanied by dropped cornucopia of COL1A1 and COL1A2 protein but not their mRNA, the two factors of collagenI. constantly, IL- 1β treatment of dressed primary mortal amnion fibroblasts reduced COL1A1 and COL1A2 protein but not their mRNA cornucopia along with increased cornucopia of autophagy activation labels, including the microtubule- associated protein L chain 3β II/ I rate and autophagy- related 7( ATG7) in the cells. T...
Read more